We are analyzing https://link.springer.com/article/10.1007/s00280-009-0975-z.

Title:
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer | Cancer Chemotherapy and Pharmacology
Description:
To evaluate the efficacy and safety of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in metastatic breast cancer (MBC). Patients with measurable, progressive, or recurrent MBC whose primary tumor expressed ≥1 ErbB receptor were randomized to the following CI-1033 regimens: 50 mg (arm A) or 150 mg (arm B) daily without rest period, or 450 mg/day × 14 days every 21 days (arm C). The primary endpoint was 1-year progression-free survival (PFS). Overall, 194 patients were treated. One-year PFS estimates were 3.8, 2.0, and 4.6%; median PFS was 61, 56, and 58 days; and investigator-assessed overall response rates were 1.5, 1.5, and 7.3%, in arms A, B, and C, respectively. Response duration was 110–419 days. In arm C, response (18.8 vs. 2.6%) and 1-year overall survival rates (86.7 vs. 47.5%) were greater in patients with HER2-positive versus HER2-negative tumors. The incidence of grade 3/4 adverse events (AEs) was dose-dependent, affecting 10.3, 48.6, and 80.4% of patients in arms A, B and C, respectively. The most common grade 3/4, treatment-related AEs were diarrhea, asthenia, and stomatitis. Arm C enrollment was prematurely discontinued due to a high frequency of grade 3/4 AEs. Single-agent CI-1033 did not show clinically meaningful activity in heavily pretreated patients with MBC expressing ≥1 ErbB receptor. Antitumor activity was observed in arm C patients with HER2-positive tumors. However, only the 50 mg dose was well tolerated, and the highest dose reached unacceptable levels of toxicity.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, article, google, scholar, patients, breast, pubmed, phase, cas, study, clin, metastatic, receptor, oncol, inhibitor, panerbb, research, usa, randomized, advanced, rixe, efficacy, safety, arm, access, tyrosine, treatment, clinical, privacy, cookies, content, abstract, herpositive, tumors, trastuzumab, kinase, oral, res, institute, multicenter, trial, center, publish, search, chemotherapy, tyrosinekinase, olivier, franco, stephen, days,

Topics {✒️}

androgen receptor-positive metastatic irreversible pan-erbb inhibitor month download article/chapter tyrosine kinase inhibitor metastatic breast cancer receptor tyrosine kinases her2-positive tumors small-cell lung cancer advanced breast cancer 1-year progression-free survival article cancer chemotherapy pharmacology article full article pdf advanced solid tumors national cancer institute anticancer therapies previously treated advanced privacy choices/manage cookies phase ii trial breast cancer related subjects phase ii study tumor pharmacodynamic study study center staff acknowledge editorial support article rixe heavily pretreated patients european economic area check access instant access clinical research department refractory cancer dose-finding study pharmacology aims prematurely discontinued due food effect study /food effect study critical end point lo russo pm open-label m77001 study group clinical trial team cancer research conditions privacy policy clinical oncology/college dr patrice herait california san francisco metastatic disease treatment-related aes article log

Questions {❓}

Rixe O, Fojo T (2007) Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
         description:To evaluate the efficacy and safety of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in metastatic breast cancer (MBC). Patients with measurable, progressive, or recurrent MBC whose primary tumor expressed ≥1 ErbB receptor were randomized to the following CI-1033 regimens: 50 mg (arm A) or 150 mg (arm B) daily without rest period, or 450 mg/day × 14 days every 21 days (arm C). The primary endpoint was 1-year progression-free survival (PFS). Overall, 194 patients were treated. One-year PFS estimates were 3.8, 2.0, and 4.6%; median PFS was 61, 56, and 58 days; and investigator-assessed overall response rates were 1.5, 1.5, and 7.3%, in arms A, B, and C, respectively. Response duration was 110–419 days. In arm C, response (18.8 vs. 2.6%) and 1-year overall survival rates (86.7 vs. 47.5%) were greater in patients with HER2-positive versus HER2-negative tumors. The incidence of grade 3/4 adverse events (AEs) was dose-dependent, affecting 10.3, 48.6, and 80.4% of patients in arms A, B and C, respectively. The most common grade 3/4, treatment-related AEs were diarrhea, asthenia, and stomatitis. Arm C enrollment was prematurely discontinued due to a high frequency of grade 3/4 AEs. Single-agent CI-1033 did not show clinically meaningful activity in heavily pretreated patients with MBC expressing ≥1 ErbB receptor. Antitumor activity was observed in arm C patients with HER2-positive tumors. However, only the 50 mg dose was well tolerated, and the highest dose reached unacceptable levels of toxicity.
         datePublished:2009-03-18T00:00:00Z
         dateModified:2009-03-18T00:00:00Z
         pageStart:1139
         pageEnd:1148
         sameAs:https://doi.org/10.1007/s00280-009-0975-z
         keywords:
            CI-1033
            Pan-ErbB receptor tyrosine-kinase inhibitor
            Metastatic breast cancer
            Efficacy
            Safety
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-009-0975-z/MediaObjects/280_2009_975_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-009-0975-z/MediaObjects/280_2009_975_Fig2_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:64
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Olivier Rixe
               affiliation:
                     name:Hopital de la Pitié Salpêtrière, APHP
                     address:
                        name:Hopital de la Pitié Salpêtrière, APHP, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:National Cancer Institute
                     address:
                        name:Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sandra X. Franco
               affiliation:
                     name:Memorial Cancer Institute
                     address:
                        name:Memorial Cancer Institute, Hollywood, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Denise A. Yardley
               affiliation:
                     name:The Sarah Cannon Research Institute
                     address:
                        name:The Sarah Cannon Research Institute, Nashville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen R. Johnston
               affiliation:
                     name:Royal Marsden Hospital
                     address:
                        name:Royal Marsden Hospital, London/Sutton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Miguel Martin
               affiliation:
                     name:Hospital Clinico San Carlos
                     address:
                        name:Hospital Clinico San Carlos, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Banu K. Arun
               affiliation:
                     name:University of Texas MD Anderson Cancer Center
                     address:
                        name:University of Texas MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephen P. Letrent
               affiliation:
                     name:Pfizer Global Research and Development
                     address:
                        name:Pfizer Global Research and Development, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hope S. Rugo
               affiliation:
                     name:University of California San Francisco
                     address:
                        name:Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
      description:To evaluate the efficacy and safety of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in metastatic breast cancer (MBC). Patients with measurable, progressive, or recurrent MBC whose primary tumor expressed ≥1 ErbB receptor were randomized to the following CI-1033 regimens: 50 mg (arm A) or 150 mg (arm B) daily without rest period, or 450 mg/day × 14 days every 21 days (arm C). The primary endpoint was 1-year progression-free survival (PFS). Overall, 194 patients were treated. One-year PFS estimates were 3.8, 2.0, and 4.6%; median PFS was 61, 56, and 58 days; and investigator-assessed overall response rates were 1.5, 1.5, and 7.3%, in arms A, B, and C, respectively. Response duration was 110–419 days. In arm C, response (18.8 vs. 2.6%) and 1-year overall survival rates (86.7 vs. 47.5%) were greater in patients with HER2-positive versus HER2-negative tumors. The incidence of grade 3/4 adverse events (AEs) was dose-dependent, affecting 10.3, 48.6, and 80.4% of patients in arms A, B and C, respectively. The most common grade 3/4, treatment-related AEs were diarrhea, asthenia, and stomatitis. Arm C enrollment was prematurely discontinued due to a high frequency of grade 3/4 AEs. Single-agent CI-1033 did not show clinically meaningful activity in heavily pretreated patients with MBC expressing ≥1 ErbB receptor. Antitumor activity was observed in arm C patients with HER2-positive tumors. However, only the 50 mg dose was well tolerated, and the highest dose reached unacceptable levels of toxicity.
      datePublished:2009-03-18T00:00:00Z
      dateModified:2009-03-18T00:00:00Z
      pageStart:1139
      pageEnd:1148
      sameAs:https://doi.org/10.1007/s00280-009-0975-z
      keywords:
         CI-1033
         Pan-ErbB receptor tyrosine-kinase inhibitor
         Metastatic breast cancer
         Efficacy
         Safety
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-009-0975-z/MediaObjects/280_2009_975_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-009-0975-z/MediaObjects/280_2009_975_Fig2_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:64
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Olivier Rixe
            affiliation:
                  name:Hopital de la Pitié Salpêtrière, APHP
                  address:
                     name:Hopital de la Pitié Salpêtrière, APHP, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:National Cancer Institute
                  address:
                     name:Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sandra X. Franco
            affiliation:
                  name:Memorial Cancer Institute
                  address:
                     name:Memorial Cancer Institute, Hollywood, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Denise A. Yardley
            affiliation:
                  name:The Sarah Cannon Research Institute
                  address:
                     name:The Sarah Cannon Research Institute, Nashville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen R. Johnston
            affiliation:
                  name:Royal Marsden Hospital
                  address:
                     name:Royal Marsden Hospital, London/Sutton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Miguel Martin
            affiliation:
                  name:Hospital Clinico San Carlos
                  address:
                     name:Hospital Clinico San Carlos, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Banu K. Arun
            affiliation:
                  name:University of Texas MD Anderson Cancer Center
                  address:
                     name:University of Texas MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephen P. Letrent
            affiliation:
                  name:Pfizer Global Research and Development
                  address:
                     name:Pfizer Global Research and Development, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hope S. Rugo
            affiliation:
                  name:University of California San Francisco
                  address:
                     name:Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:64
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hopital de la Pitié Salpêtrière, APHP
      address:
         name:Hopital de la Pitié Salpêtrière, APHP, Paris, France
         type:PostalAddress
      name:National Cancer Institute
      address:
         name:Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
         type:PostalAddress
      name:Memorial Cancer Institute
      address:
         name:Memorial Cancer Institute, Hollywood, USA
         type:PostalAddress
      name:The Sarah Cannon Research Institute
      address:
         name:The Sarah Cannon Research Institute, Nashville, USA
         type:PostalAddress
      name:Royal Marsden Hospital
      address:
         name:Royal Marsden Hospital, London/Sutton, UK
         type:PostalAddress
      name:Hospital Clinico San Carlos
      address:
         name:Hospital Clinico San Carlos, Madrid, Spain
         type:PostalAddress
      name:University of Texas MD Anderson Cancer Center
      address:
         name:University of Texas MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:Pfizer Global Research and Development
      address:
         name:Pfizer Global Research and Development, San Diego, USA
         type:PostalAddress
      name:University of California San Francisco
      address:
         name:Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Olivier Rixe
      affiliation:
            name:Hopital de la Pitié Salpêtrière, APHP
            address:
               name:Hopital de la Pitié Salpêtrière, APHP, Paris, France
               type:PostalAddress
            type:Organization
            name:National Cancer Institute
            address:
               name:Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sandra X. Franco
      affiliation:
            name:Memorial Cancer Institute
            address:
               name:Memorial Cancer Institute, Hollywood, USA
               type:PostalAddress
            type:Organization
      name:Denise A. Yardley
      affiliation:
            name:The Sarah Cannon Research Institute
            address:
               name:The Sarah Cannon Research Institute, Nashville, USA
               type:PostalAddress
            type:Organization
      name:Stephen R. Johnston
      affiliation:
            name:Royal Marsden Hospital
            address:
               name:Royal Marsden Hospital, London/Sutton, UK
               type:PostalAddress
            type:Organization
      name:Miguel Martin
      affiliation:
            name:Hospital Clinico San Carlos
            address:
               name:Hospital Clinico San Carlos, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Banu K. Arun
      affiliation:
            name:University of Texas MD Anderson Cancer Center
            address:
               name:University of Texas MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Stephen P. Letrent
      affiliation:
            name:Pfizer Global Research and Development
            address:
               name:Pfizer Global Research and Development, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Hope S. Rugo
      affiliation:
            name:University of California San Francisco
            address:
               name:Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Hopital de la Pitié Salpêtrière, APHP, Paris, France
      name:Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
      name:Memorial Cancer Institute, Hollywood, USA
      name:The Sarah Cannon Research Institute, Nashville, USA
      name:Royal Marsden Hospital, London/Sutton, UK
      name:Hospital Clinico San Carlos, Madrid, Spain
      name:University of Texas MD Anderson Cancer Center, Houston, USA
      name:Pfizer Global Research and Development, San Diego, USA
      name:Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(103)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.96s.

LINK . SPRINGER . COM {}